SEC Tracker
Get the app

Celcuity CELC

Celcuity Q1 FY25: net loss $37.0M; diluted EPS −$0.86

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.2
Material contract
Exhibit 10.3
Material contract

Key figures from this report

These are the numbers Celcuity reported for Q1 FY25, the quarter ended Mar 31, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$37.0MAgainst −$21.6M in Q1 FY2410-Q income statement, on EDGAR
  2. Diluted EPS−$0.86Against −$0.64 in Q1 FY2410-Q income statement, on EDGAR
  3. Cash and cash equivalents$16.5M−47% from $31.2M in Q1 FY24Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  4. Cash from operations−$35.9MAgainst −$17.1M in Q1 FY2410-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Celcuity files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8071 and related industry codes: the same peer list as the financial tables.

  1. Fortrea Holdings FTRE public float $448M, Jun 30, 2025
  2. Castle Biosciences CSTL public float $576M, Jun 30, 2025
  3. Personalis PSNL public float $578M, Jun 30, 2025
  4. Fulgent Genetics FLGT public float $284M, Jun 30, 2025
  5. CareDx CDNA public float $1.0B, Jun 30, 2025